{"id":"vb-111-bevacizumab","safety":{"commonSideEffects":[{"rate":"null","effect":"Hypertension"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting VEGF, VB-111 and bevacizumab aim to reduce angiogenesis and tumor growth. VB-111's mechanism is based on its ability to bind to and inhibit the expression of VEGF mRNA, whereas bevacizumab directly binds to VEGF, preventing it from interacting with its receptor.","oneSentence":"VB-111 is a targeted therapy that works by inhibiting the expression of vascular endothelial growth factor (VEGF) mRNA, while bevacizumab is a monoclonal antibody that directly binds to VEGF.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:19.249Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glioblastoma"}]},"trialDetails":[{"nctId":"NCT04406272","phase":"PHASE2","title":"VB-111 in Surgically Accessible Recurrent/Progressive GBM","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-08-01","conditions":"Glioblastoma, Recurrent Glioblastoma","enrollment":15},{"nctId":"NCT01260506","phase":"PHASE1, PHASE2","title":"Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Vascular Biogenics Ltd. operating as VBL Therapeutics","startDate":"2010-12","conditions":"Glioblastoma Multiforme","enrollment":75},{"nctId":"NCT02511405","phase":"PHASE3","title":"A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)","status":"COMPLETED","sponsor":"Vascular Biogenics Ltd. operating as VBL Therapeutics","startDate":"2015-08","conditions":"Glioblastoma","enrollment":252}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VB-111 + bevacizumab","genericName":"VB-111 + bevacizumab","companyName":"Vascular Biogenics Ltd. operating as VBL Therapeutics","companyId":"vascular-biogenics-ltd-operating-as-vbl-therapeutics","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VB-111 is a targeted therapy that works by inhibiting the expression of vascular endothelial growth factor (VEGF) mRNA, while bevacizumab is a monoclonal antibody that directly binds to VEGF. Used for Glioblastoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}